635 related articles for article (PubMed ID: 16325880)
21. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
[TBL] [Abstract][Full Text] [Related]
22. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
23. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
[TBL] [Abstract][Full Text] [Related]
24. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
25. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
26. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
27. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
28. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
[TBL] [Abstract][Full Text] [Related]
29. Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys.
Barouch DH; Letvin NL
Dev Biol (Basel); 2000; 104():85-92. PubMed ID: 11713828
[TBL] [Abstract][Full Text] [Related]
30. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
Cristillo AD; Galmin L; Restrepo S; Hudacik L; Suschak J; Lewis B; Draghia-Akli R; Aziz N; Weiss D; Markham P; Pal R
Biochem Biophys Res Commun; 2008 May; 370(1):22-6. PubMed ID: 18329382
[TBL] [Abstract][Full Text] [Related]
33. Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust immune responses that last to adulthood.
Rigato PO; Maciel M; Goldoni AL; Piubelli O; de Brito CA; Fusaro AE; Eurico de Alencar LX; August T; Azevedo Marques ET; da Silva Duarte AJ; Sato MN
Virology; 2010 Oct; 406(1):37-47. PubMed ID: 20667577
[TBL] [Abstract][Full Text] [Related]
34. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
35. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
36. Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice.
Goldoni AL; Maciel M; Rigato PO; Piubelli O; de Brito CA; Melo A; Marques ET; August JT; Duarte AJ; Sato MN
Immunobiology; 2011 Apr; 216(4):505-12. PubMed ID: 20870310
[TBL] [Abstract][Full Text] [Related]
37. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.
Stambas J; Brown SA; Gutierrez A; Sealy R; Yue W; Jones B; Lockey TD; Zirkel A; Freiden P; Brown B; Surman S; Coleclough C; Slobod KS; Doherty PC; Hurwitz JL
Vaccine; 2005 Mar; 23(19):2454-64. PubMed ID: 15752831
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.
Vinner L; Wee EG; Patel S; Corbet S; Gao GP; Nielsen C; Wilson JM; Ertl HCJ; Hanke T; Fomsgaard A
J Gen Virol; 2003 Jan; 84(Pt 1):203-213. PubMed ID: 12533717
[TBL] [Abstract][Full Text] [Related]
39. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
40. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.
Bråve A; Hallengärd D; Malm M; Blazevic V; Rollman E; Stanescu I; Krohn K
Vaccine; 2009 Jan; 27(2):184-6. PubMed ID: 18992294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]